FDA-awarded RMAT designations continue to surge in 2025, reveals GlobalData
From the article
Since the FDA first awarded a regenerative medicine advanced therapeutic (RMAT) designation in 2017, activity in this space remained relatively modest until 2023. However, the number of RMAT designations increased sharply in 2024, reaching a record of 48 RMAT designations in 2025, reflecting the expanding regenerative medicine landscape and suggesting that a larger number of […]
Continue reading on globaldata.comYou might also wanna read
China creates new regulatory pathway to accelerate access to advanced biomedical therapies
China has established a new regulatory "tech track" for advanced therapies like personalized cancer treatments, cell and gene therapies, and
biopharmadive.com·24d ago
FDA Draft Guidance Allows Gene Therapy Companies to Leverage Existing Data for Faster Product Approvals
The FDA released a new draft guidance on June 2 titled "Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorpo
jdsupra.com·26d ago
Modelling Study Projects Rapid Growth in Radioligand Therapy Patient Populations Across EU and UK Healthcare Systems
This modelling study estimates the future patient populations eligible for radioligand therapies (RLTs) across EU-27 member states and the U
thelancet.com·1mo ago
ACGT Summit 2026 Marks 25 Years of Progress in Cancer Cell and Gene Therapy
The ACGT Summit 2026 marked the 25th anniversary of the Alliance for Cancer Gene Therapy, celebrating the evolution of cell and gene therapy
acgtfoundation.org·22d ago
2026 Regeneron ISEF finalists apply biochemistry and AI to address the mental health crisis
This article highlights how 2026 Regeneron ISEF finalists are using biochemistry, AI, and medical research to develop solutions for the ment
societyforscience.org·19d ago
Towards mRNA therapeutics 2.0
doi.org·3d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.